Aspirin Use for Secondary Prevention Amid Negative Messaging in Patients With Cardiovascular Disease
-
By
-
Jeremy R. Van’t Hof
-
Sue Duval
-
Niki Oldenburg
-
Milton Eder
-
Russell V. Luepker
-
June 4, 2026
-
Clinical Scorecard: Aspirin Administration for Secondary Prevention in the Context of Adverse Perceptions Among Cardiovascular Disease Patients
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Adults aged 45 to 79 years with ASCVD, including both genders. |
| Care Setting | |
Key Highlights
- Clarify the implications of physician recommendations on aspirin cessation.
Guideline-Based Recommendations
Diagnosis
Management
- Aspirin is recommended for secondary prevention in adults with ASCVD, as per current guidelines.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Adults aged 45 to 79 years with ASCVD, including 38% females.
Stable aspirin use for secondary prevention despite negative messaging about primary prevention.
Clinical Best Practices
- Provide specific strategies for addressing patient concerns regarding aspirin use.
Related Resources & Content
